Major Conferences & Late-Breaking Trials

Early TAVR reduced MACE 16% vs. watchful waiting over 3.8 years. Challenges current surveillance-only guidelines for asymptomatic severe AS. Simultaneously published in NEJM.

Early TAVR did NOT reduce mortality in AS + myocardial fibrosis (14% vs 13%), but reduced hospitalizations (6% vs 17%) and improved symptom control. Contrasts with EARLY TAVR findings.

TAVR in HFrEF + moderate AS: no significant benefit over medical therapy. No advantage to earlier TAVR in this population. Informs heart team decision-making at the HF/AS intersection.

Sustained QoL improvement and TR reduction at 2 years. Validated FDA approval. No survival benefit but clinically meaningful symptom relief. Sets benchmark for tricuspid TEER long-term performance.

First pivotal RCT for transcatheter tricuspid valve replacement: Evoque TTVR vs. medical therapy showed significant QoL improvement, TR elimination, and functional benefit. Landmark trial for TTVR field.

Quantitative flow ratio (QFR) non-inferior to wire-based FFR for guiding revascularization decisions. Supports wire-free physiology-guided PCI with QFR in stable CAD.

AI-based fully automated quantitative coronary angiography non-inferior to OCT guidance for coronary stent implantation in a multicenter RCT. AI enters the imaging-guided PCI space.

First dedicated PAD outcomes trial with GLP-1 agonist: semaglutide significantly improved 6MWT functional capacity in T2DM + PAD. Expands GLP-1 benefit beyond CV mortality to functional outcomes in vascular disease.

Oral PCSK9 inhibitor produced significant LDL-C reduction with promising safety profile. First oral agent in this class — potential to eliminate injectable PCSK9i barrier to adherence.

Colchicine did NOT significantly slow coronary atherosclerosis progression in stable CAD patients on statin therapy. Contextualizes the anti-inflammatory strategy — benefit may be limited to acute/post-MI settings.

Real-world data: micro-axial flow pump as initial MCS in SCAI stage D/E cardiogenic shock may be insufficient. Supports earlier escalation to higher-level hemodynamic support in advanced shock.

Double-blind RCT of autologous cell therapy in HFrEF. Novel regenerative approach. Results presented at ACC.25.

Extended anticoagulation in cancer-associated VTE: reduced-dose apixaban safety and efficacy data. Informs anticoagulation strategy in oncology patients at high bleeding risk.

731 patients: tirzepatide (GLP-1/GIP) vs. placebo in HFpEF + obesity. Significant improvement in 6MWT, KCCQ, and weight loss. Major advance for HFpEF + obesity — currently the largest unmet need in HF management.

Single-dose CRISPR-Cas9 gene editing therapy: sustained TTR protein reduction in ATTR-CM patients. Historic landmark in gene therapy — potential one-time treatment for a previously fatal progressive disease.

Open-label extension: acoramidis (AG10) reduces all-cause mortality and CV hospitalization in ATTR-CM long term. Confirms durability of TTR stabilization benefit.

1,600 post-ablation AF patients: Watchman FLX non-inferior to OAC for stroke prevention with significantly less major bleeding. Strengthens LAA occlusion as post-ablation anticoagulation alternative.

Ablation superior to escalated AAD for reducing VT recurrence and ICD shocks in ischemic cardiomyopathy. Supports ablation as first-line VT strategy in structural heart disease. Published NEJM.

Adding linear ablation + EIVOM to PVI significantly improved 12-month freedom from atrial arrhythmias in persistent AF. Published JAMA. Supports more aggressive ablation strategy for persistent AF.

5-year data: Amulet non-inferior to Watchman 2.5 for stroke/embolism with consistent long-term safety. Confirms durable LAA closure protection over 5 years.

Intensive BP (SBP <120 mmHg) vs. standard (<140) in T2DM: significant reduction in MACE and stroke over 4.2 years. Supports aggressive BP targets in high-risk diabetic patients.

Post-MI: colchicine reduced MACE (inflammation hypothesis confirmed). Spironolactone: no benefit in non-HF post-MI. Key data separating anti-inflammatory vs. mineralocorticoid strategies after MI.

Pooled individual patient data from 2 large RCTs: routine SENTINEL cerebral embolic protection did NOT reduce peri-procedural stroke. Does NOT support routine CEP use during TAVR. Major practice-changing finding.

Updated EARLY TAVR analysis: cardiac damage patterns in asymptomatic severe AS and how early TAVR modifies disease progression. Further supports considering earlier intervention before cardiac damage accumulates.

Hotline bundle: TRILUMINATE 2-year follow-up confirms durable TR reduction; TRI-SCORE validates mortality risk prediction post-T-TEER; FATE registry characterizes failed T-TEER outcomes; bRIGHT real-world data confirms QoL benefit.

EuroPCR 2025 hotline: impact of T-TEER on prognosis specifically in atrial functional MR — a growing and distinct etiology of mitral regurgitation with different pathophysiology and outcomes compared to primary MR.

First RCT: FFR-guided PCI superior to angiography-guided in intermediate CAD + severe AS undergoing TAVR. Lower 12-month MACCE with FFR guidance. Directly relevant to structural heart + coronary intersection.

1-month DAPT then prasugrel monotherapy: significantly reduced bleeding without increasing ischaemic events vs. standard DAPT in ACS. Patient-tailored antiplatelet strategy — especially relevant for high bleeding risk.

FFR-guided complete revascularisation maintains durable reduction in repeat revascularisation at 10 years vs. IRA-only treatment in STEMI. No mortality benefit but sustained ischaemia prevention confirmed long-term.

BALI: IVL vs. conventional balloon prep in severely calcified lesions — first dedicated RCT for IVL vs. conventional. EMPOWER CAD: dedicated female cohort data for IVL in calcified coronary disease.

431 patients, SCAI Stage B CS: 26% experienced deterioration, escalation, or in-hospital death. Most common etiologies: HF (35%), arrhythmias (22%), AMI (9%). RHC performed in only 8.6% — underutilization highlighted.

Registry-based comparison of stented vs. non-stented CTO PCI — clinical outcomes data informing completeness of revascularization decisions in chronic total occlusion intervention.

Novel balloon-assisted modification of the anterior mitral leaflet (BAML) technique data for structural heart interventions — expanding the toolbox for complex TMVR and valve-in-valve procedures.

Insights from FAVOR III China: identifying clinical, angiographic, and procedural features predicting MACE despite optimal QFR-guided PCI. Helps select patients who may need additional imaging guidance beyond QFR.

National Medicare data on PCI performed in ambulatory surgery centers: volume trends, procedural outcomes, and safety profile. Informs the expanding role of non-hospital-based PCI in appropriate patients.

First RCT comparing TAVR vs. SAVR specifically in low-risk patients aged 70 or younger — directly addresses valve durability concerns in younger patients considering transcatheter approach.

Real-world STS/ACC TVT Registry analysis: impact of cerebral embolic protection devices on disabling stroke. Large-scale registry data to complement/contrast with PROTECTED TAVR RCT findings.

Long-term PARTNER trial data in small annulus patients — critical for informing TAVR vs. SAVR decisions in patients with challenging anatomy where prosthesis-patient mismatch risk is highest.

Detailed cardiac MRI and CT imaging substudy from TRILUMINATE pivotal: quantifying right heart remodeling with tricuspid regurgitation and response to T-TEER — informs optimal patient selection and timing of intervention.

Full program featured 12 late-breaking trials organized by valve (aortic Day 1, tricuspid Day 2, mitral Day 3), plus 20+ live cases from 17 institutions. Full trial list at nyvalvesconference.com.

Sessions on AI-assisted pre-procedural planning using patient anatomy models for optimal device selection. AI strategies for structural interventions highlighted by Dr. Yiannis Chatzizisis (UM). Major conference theme 2025.

Case-based plenary featuring challenging structural cases. Presenters included Dr. Nicolas Van Mieghem, Dr. William O'Neill, Dr. Jeffrey Popma — updates on upcoming TAVR trials and the role of AI in identifying undertreated severe AS.

Focused symposia on IVUS and OCT as two powerful coronary imaging technologies for PCI guidance. Highlighted practical imaging-guided PCI strategies with case-based demonstrations from structural and interventional faculty.

Annual CRT meeting focuses on IVUS/OCT-guided PCI, bifurcation techniques, atherectomy strategies, structural heart interventions, and peripheral vascular. Strong emphasis on practical case-based learning from complex operators.

CRF announced the launch of a dedicated Complex Coronary Summit debuting in 2027 — signaling the growing importance of complex PCI as a distinct subspecialty. CRT 2026 continues as the interim home for complex coronary content.

Full searchable library of presentations, late-breaking trials, expert interviews, and trial summaries from TCT, New York Valves, CRT, and all CRF-produced conferences. Free access to slides and video for many sessions.

TCT 2025 coming October 2025 — late-breaking trials to be announced. Abstract deadline typically June–July. Structural heart, complex PCI, MCS, and cardiogenic shock featured prominently. Register early for best rates.

Most anticipated LAA trial: largest randomized comparison of Watchman FLX vs. direct OAC in general AF population. Primary results at ACC.26 March 2026. Will define the future of LAA closure indications.

First large RCT: catheter-directed thrombolysis vs. anticoagulation alone in intermediate-high-risk PE. Defines whether CDT should become standard of care for this high-risk PE population.

RCT: Impella-based LV unloading before reperfusion in anterior STEMI without shock. Tests the hypothesis that mechanical unloading before primary PCI reduces infarct size and improves outcomes.

Three major structural trials: SURVIV (redo MVS vs. transcatheter MViV), TRI-FR 2-year outcomes (tricuspid TEER), and first RCT of TAVR without routine concomitant PCI in CAD patients.